Pomegra
Suki raised a $90M Series E led by Healthier Capital to move its AI scribe into referrals and prior authorizations, with valuation undisclosed.
Key Takeaways
- Suki closed a $90M Series E led by new investor Healthier Capital, announced October 13, 2026.
- Total funding now exceeds $250M; the company did not disclose its valuation.
- Patient encounters on its platform grew 190% year over year in 2026.
Lead
Suki, the Redwood City, California, maker of ambient clinical documentation software, announced on October 13, 2026 that it had closed a $90 million Series E round. Healthier Capital led the financing, and Crosslink Capital and Hercules Capital joined as new investors. The company will spend the money on its AI, its commercial team and its partner ecosystem, and on software that completes tasks after a patient visit ends. Suki did not disclose a valuation.
Who Invested in the Series E?
Healthier Capital led the round, and Crosslink Capital and Hercules Capital entered as first-time backers. Every existing institutional investor took part, including Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures. Aman Mahajan, a partner at Healthier Capital, joined Suki's board as part of the deal.
Hercules Capital is better known as a lender to late-stage venture-backed companies than as a pure equity investor. The company has not published how much of the $90 million is equity and how much is debt, so the headline figure is not directly comparable with all-equity rounds at competitors.
What Does Suki Plan to Do With the Money?
Suki plans to extend its product from writing clinical notes to completing the administrative work that follows them. Those tasks include drafting referrals, submitting prior authorizations, placing orders and scheduling follow-up appointments, without a physician re-entering the information.
Chief executive and founder Punit Soni framed the strategy around restraint as much as ambition. "I think you should raise only how much you need," he told Healthcare Dive. "Having a little bit of starvation creates discipline."
The company also works with more than 30 technology partners, including Optum, Zoom and athenahealth, which embed Suki's AI inside their own products. Suki has said its platform integrates with the major electronic health record systems, among them Epic, Oracle Health and MEDITECH.
How Does the Round Compare With Suki's Last Raise?
The Series E is larger and later than the $70 million Series D that Hedosophia led in October 2024. That round was reported at a valuation of roughly $500 million. Suki has raised more than $250 million across five rounds, up from about $168 million after the Series D.
The new valuation is undisclosed, so the step-up cannot be measured. Rounds that include a venture lender and omit a price are a common pattern for companies that prefer not to publish a number that might look unflattering next to rivals. They can also reflect a strong negotiating position. Without the figure, outsiders cannot tell which applies here.
How Big Is Suki Relative to Its Rivals?
Suki is smaller than the best-funded names in ambient documentation. Abridge reported a $300 million Series E in 2025 at a valuation of about $5.3 billion, and Ambience Healthcare raised $243 million in the same period. Microsoft's Nuance DAX Copilot sells into the same health systems with the distribution of a large software vendor.
Against that field, Suki's growth figures are respectable but not dominant. Patient encounters rose 190% year over year in 2026, and the company reports that its partner channel's revenue grew roughly tenfold over two years. One outlet reported a 2026 revenue projection of $60 million to $80 million, a figure the company has not confirmed in its own announcement.
The company's customer count is stated inconsistently. Coverage of the announcement cites both more than 250 healthcare organizations and more than 450, which likely reflects a difference between direct customers and organizations reached through partners.
Why Move Beyond Note-Taking?
Ambient scribing is becoming a commodity feature. EHR vendors and large platforms now bundle comparable tools, and athenahealth and Zoom already resell Suki's own technology under their brands. Differentiating on note quality alone gets harder as buyers compare near-identical products.
Administrative workflows are a larger and stickier target. Prior authorization and referral handling touch revenue and staffing directly, which makes them easier to price than minutes saved per note. They are also harder to get right, because errors carry billing and patient-safety consequences.
Accuracy remains an open issue for the category. A 2025 study from MedStar Health and Georgetown found that 70% of AI-generated clinical notes in its sample contained at least one error. An AAFP Innovation Lab study put documentation time savings at about 72% for Suki users, though the two findings measure different things.
What Comes Next for Suki?
The next test is whether Suki can ship autonomous workflows that health systems trust without clinician review of every step. That requires integrations with payers, order systems and scheduling tools, not just EHR note fields.
Investor mix offers one hint. A late-stage lender joining the cap table often precedes a larger capital markets event, though Suki has made no such announcement. If the agent products land, a higher-priced round or a strategic sale becomes plausible. If they stall, Suki will face better-funded rivals while selling a feature that its own partners can also offer.
Outlook
Suki enters its next phase with more than $250 million raised, a new lead investor and a product plan aimed at the administrative work around the exam room. The undisclosed valuation and the unspecified debt component leave the quality of the round hard to judge. Execution on referrals and prior authorizations, rather than note volume, will decide whether the company closes the gap with Abridge and Ambience.
